This recruiting study focuses on schizophrenia and currently lists sites or participation links in Egypt.
This study is comparing Empagliflozin with Group 1 as control group for people with Sodium-glucose Transport Protein Two Inhibitor,Metabolic Deficits Caused by Antipsychotics. Participants receive Empagliflozin or Group 1 as control group and complete study visits and assessments. Some participants may receive Group 1 as control group instead of the study treatment, and direct benefit is not guaranteed.
The official record does not clearly describe the visit format, so the practical details are best checked directly in the source. Participation appears to involve study activities and follow-up chosen by the research team. The main fit and exclusions are best confirmed in the eligibility section of the official record. The phase details are not clearly stated here.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may help improve understanding of your condition.
It requires regular follow-up, often through questionnaires or interviews.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com